Published in J Cereb Blood Flow Metab on September 01, 2003
11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls. J Nucl Med (2009) 1.99
How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems. Neuropharmacology (2008) 1.56
High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People. Biol Psychiatry (2014) 1.54
Fluoxetine administered to juvenile monkeys: effects on the serotonin transporter and behavior. Am J Psychiatry (2014) 1.54
The 5-HT1A receptor and 5-HT transporter in temporal lobe epilepsy. Neurology (2013) 1.51
Risky decision-making and ventral striatal dopamine responses to amphetamine: a positron emission tomography [(11)C]raclopride study in healthy adults. Neuroimage (2015) 1.48
Decreased neurokinin-1 (substance P) receptor binding in patients with panic disorder: positron emission tomographic study with [18F]SPA-RQ. Biol Psychiatry (2009) 1.47
Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci (2007) 1.46
Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry (2010) 1.44
Image-derived input function for brain PET studies: many challenges and few opportunities. J Cereb Blood Flow Metab (2011) 1.42
18F-Mefway PET imaging of serotonin 1A receptors in humans: a comparison with 18F-FCWAY. PLoS One (2015) 1.42
Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study. Brain (2010) 1.35
Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology (2007) 1.30
Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci U S A (2011) 1.29
Striatal dopaminergic denervation and gait in healthy adults. Exp Brain Res (2007) 1.21
Honesty mediates the relationship between serotonin and reaction to unfairness. Proc Natl Acad Sci U S A (2012) 1.20
Kinetic modeling of the serotonin 5-HT(1B) receptor radioligand [(11)C]P943 in humans. J Cereb Blood Flow Metab (2009) 1.19
Midbrain serotonin transporter binding potential measured with [11C]DASB is affected by serotonin transporter genotype. J Neural Transm (Vienna) (2007) 1.19
Small-animal PET imaging of amyloid-beta plaques with [11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease. PLoS One (2012) 1.18
Persistent dopamine functions of neurons derived from embryonic stem cells in a rodent model of Parkinson disease. Stem Cells (2006) 1.16
Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET. Mol Psychiatry (2012) 1.16
Association of posttraumatic stress disorder with reduced in vivo norepinephrine transporter availability in the locus coeruleus. JAMA Psychiatry (2013) 1.14
Pancreatic beta cell mass PET imaging and quantification with [11C]DTBZ and [18F]FP-(+)-DTBZ in rodent models of diabetes. Mol Imaging Biol (2010) 1.14
Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder. Psychopharmacology (Berl) (2010) 1.13
D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: a PET study in a receptor internalization-deficient mouse model. Neuroimage (2010) 1.12
Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2. Psychopharmacology (Berl) (2006) 1.10
Dysregulation of D₂-mediated dopamine transmission in monkeys after chronic escalating methamphetamine exposure. J Neurosci (2012) 1.09
Selective hyposmia in Parkinson disease: association with hippocampal dopamine activity. Neurosci Lett (2008) 1.08
A consistent and efficient graphical analysis method to improve the quantification of reversible tracer binding in radioligand receptor dynamic PET studies. Neuroimage (2008) 1.05
Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease. J Neurol (2007) 1.04
Serotonin transporter availability in the amygdala and bed nucleus of the stria terminalis predicts anxious temperament and brain glucose metabolic activity. J Neurosci (2009) 1.04
Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRI. Proc Natl Acad Sci U S A (2013) 1.02
Methamphetamine-induced increases in putamen gray matter associate with inhibitory control. Psychopharmacology (Berl) (2013) 1.02
Tracer kinetic modeling of [(11)C]AFM, a new PET imaging agent for the serotonin transporter. J Cereb Blood Flow Metab (2013) 1.02
Serotonin 1B receptor imaging in alcohol dependence. Biol Psychiatry (2010) 1.02
Kinetic analysis of the metabotropic glutamate subtype 5 tracer [(18)F]FPEB in bolus and bolus-plus-constant-infusion studies in humans. J Cereb Blood Flow Metab (2012) 1.01
A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology (Berl) (2006) 1.00
In vivo and in vitro validation of reference tissue models for the mGluR(5) ligand [(11)C]ABP688. J Cereb Blood Flow Metab (2010) 1.00
Serotonin transporter binding and genotype in the nonhuman primate brain using [C-11]DASB PET. Neuroimage (2009) 1.00
Microscopic lymph node tumor burden quantified by macroscopic dual-tracer molecular imaging. Nat Med (2014) 0.99
Evaluation of [(11)C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates. Neuroimage (2010) 0.99
A linear model for estimation of neurotransmitter response profiles from dynamic PET data. Neuroimage (2011) 0.99
Advantages of a dual-tracer model over reference tissue models for binding potential measurement in tumors. Phys Med Biol (2012) 0.98
Imaging inflammation in a patient with epilepsy due to focal cortical dysplasia. J Neuroimaging (2011) 0.96
The effect of early trauma exposure on serotonin type 1B receptor expression revealed by reduced selective radioligand binding. Arch Gen Psychiatry (2011) 0.95
The distribution of D2/D3 receptor binding in the adolescent rhesus monkey using small animal PET imaging. Neuroimage (2008) 0.95
Serotonin 1B receptor imaging in pathological gambling. World J Biol Psychiatry (2011) 0.94
How the serotonin transporter 5-HTTLPR polymorphism influences amygdala function: the roles of in vivo serotonin transporter expression and amygdala structure. Transl Psychiatry (2011) 0.94
Beer flavor provokes striatal dopamine release in male drinkers: mediation by family history of alcoholism. Neuropsychopharmacology (2013) 0.94
Direct estimation of kinetic parametric images for dynamic PET. Theranostics (2013) 0.94
The simplified reference tissue model: model assumption violations and their impact on binding potential. J Cereb Blood Flow Metab (2014) 0.94
Grooved pegboard test as a biomarker of nigrostriatal denervation in Parkinson's disease. Neurosci Lett (2007) 0.93
Test-retest variability of [¹¹C]raclopride-binding potential in nontreatment-seeking alcoholics. Synapse (2010) 0.92
Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - a [11C]DASB PET study. J Neural Transm (Vienna) (2007) 0.92
Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112. Neuropsychopharmacology (2008) 0.92
Central serotonin transporter levels are associated with stress hormone response and anxiety. Psychopharmacology (Berl) (2010) 0.92
A receptor-based model for dopamine-induced fMRI signal. Neuroimage (2013) 0.90
Construction and evaluation of quantitative small-animal PET probabilistic atlases for [¹⁸F]FDG and [¹⁸F]FECT functional mapping of the mouse brain. PLoS One (2013) 0.90
Quantification of alpha4beta2* nicotinic receptors in the rat brain with microPET and 2-[18F]F-A-85380. Neuroimage (2006) 0.90
Occupancy of dopamine D2/3 receptors in rat brain by endogenous dopamine measured with the agonist positron emission tomography radioligand [11C]MNPA. Synapse (2008) 0.90
Imaging serotonergic transmission with [11C]DASB-PET in depressed and non-depressed patients infected with HIV. Neuroimage (2009) 0.90
PET imaging of neurokinin-1 receptors with [(18)F]SPA-RQ in human subjects: assessment of reference tissue models and their test-retest reproducibility. Synapse (2007) 0.89
The use of alternative forms of graphical analysis to balance bias and precision in PET images. J Cereb Blood Flow Metab (2010) 0.89
Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging. Int J Neuropsychopharmacol (2014) 0.89
Decreased norepinephrine transporter availability in obesity: Positron Emission Tomography imaging with (S,S)-[(11)C]O-methylreboxetine. Neuroimage (2013) 0.89
A possible mechanism of the nucleus accumbens and ventral pallidum 5-HT1B receptors underlying the antidepressant action of ketamine: a PET study with macaques. Transl Psychiatry (2014) 0.88
Serotonin transporter genotype affects serotonin 5-HT1A binding in primates. J Neurosci (2013) 0.88
Neuroimaging and physiological evidence for involvement of glutamatergic transmission in regulation of the striatal dopaminergic system. J Neurosci (2009) 0.87
Increased synaptic dopamine in the putamen in restless legs syndrome. Sleep (2013) 0.87
Striatal D(2)/D(3) receptor availability is inversely correlated with cannabis consumption in chronic marijuana users. Drug Alcohol Depend (2012) 0.87
Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. Neurology (2013) 0.87
Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application. Transl Psychiatry (2014) 0.86
Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data. Neuroimage (2013) 0.86
Empirical Bayesian estimation in graphical analysis: a voxel-based approach for the determination of the volume of distribution in PET studies. Nucl Med Biol (2010) 0.85
Quantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imaging. Phys Med Biol (2015) 0.85
Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology (Berl) (2011) 0.85
Voxelwise quantification of [(11)C](R)-rolipram PET data: a comparison between model-based and data-driven methods. J Cereb Blood Flow Metab (2013) 0.85
Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB. Int J Neuropsychopharmacol (2010) 0.85
An optimization transfer algorithm for nonlinear parametric image reconstruction from dynamic PET data. IEEE Trans Med Imaging (2012) 0.84
Increase of 20-HETE synthase after brain ischemia in rats revealed by PET study with 11C-labeled 20-HETE synthase-specific inhibitor. J Cereb Blood Flow Metab (2012) 0.84
Functional connectivity of the dorsal and median raphe nuclei at rest. Neuroimage (2015) 0.83
Creating dynamic images of short-lived dopamine fluctuations with lp-ntPET: dopamine movies of cigarette smoking. J Vis Exp (2013) 0.83
μ-Opioid receptor availability in the amygdala is associated with smoking for negative affect relief. Psychopharmacology (Berl) (2012) 0.82
Reliability of striatal [¹¹C]raclopride binding in smokers wearing transdermal nicotine patches. Eur J Nucl Med Mol Imaging (2011) 0.82
PET brain kinetics studies of (11)C-ITMM and (11)C-ITDM,radioprobes for metabotropic glutamate receptor type 1, in a nonhuman primate. Am J Nucl Med Mol Imaging (2014) 0.82
PET imaging of acetylcholinesterase inhibitor-induced effects on α4β2 nicotinic acetylcholine receptor binding. Synapse (2013) 0.82
Dopamine beta-hydroxylase-deficient mice have normal densities of D(2) dopamine receptors in the high-affinity state based on in vivo PET imaging and in vitro radioligand binding. Synapse (2010) 0.82
Norepinephrine transporter occupancy by antidepressant in human brain using positron emission tomography with (S,S)-[18F]FMeNER-D2. Psychopharmacology (Berl) (2010) 0.82
Changes in the α4β2* nicotinic acetylcholine system during chronic controlled alcohol exposure in nonhuman primates. Drug Alcohol Depend (2014) 0.82
Comparative evaluations of norepinephrine transporter radioligands with reference tissue models in rhesus monkeys: (S,S)-[18F]FMeNER-D2 and (S,S)-[11C]MeNER. Eur J Nucl Med Mol Imaging (2009) 0.81
Mapping neuroinflammation in frontotemporal dementia with molecular PET imaging. J Neuroinflammation (2015) 0.81
Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography. Psychopharmacology (Berl) (2007) 0.81
Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: a rhesus monkey study with (S,S)-[(18)F]FMeNER-D (2). Eur J Nucl Med Mol Imaging (2009) 0.81
Cognitive function is related to fronto-striatal serotonin transporter levels--a brain PET study in young healthy subjects. Psychopharmacology (Berl) (2010) 0.81
Test-retest reproducibility of binding parameters in humans with 11C-LY2795050, an antagonist PET radiotracer for the κ opioid receptor. J Nucl Med (2015) 0.81
(18)F-MCL-524, an (18)F-Labeled Dopamine D2 and D3 Receptor Agonist Sensitive to Dopamine: A Preliminary PET Study. J Nucl Med (2014) 0.81
Non-invasive assessment of distribution volume ratios and binding potential: tissue heterogeneity and interindividually averaged time-activity curves. Eur J Nucl Med Mol Imaging (2003) 0.81
First-in-human evaluation of 18F-mefway, a PET radioligand specific to serotonin-1A receptors. J Nucl Med (2014) 0.81
Reference region approaches in PET: a comparative study on multiple radioligands. J Cereb Blood Flow Metab (2013) 0.81
In-vivo human brain molecular imaging with a brain-dedicated PET/MRI system. MAGMA (2012) 0.81
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron (2007) 6.07
When your gain is my pain and your pain is my gain: neural correlates of envy and schadenfreude. Science (2009) 3.31
Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron (2013) 3.27
Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab (2012) 2.76
Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. Int J Neuropsychopharmacol (2004) 2.64
Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab (2002) 2.58
Alpha-CaMKII deficiency causes immature dentate gyrus, a novel candidate endophenotype of psychiatric disorders. Mol Brain (2008) 2.55
Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation. Neuroimage (2007) 2.50
Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther (2006) 2.41
Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. J Cereb Blood Flow Metab (2002) 2.38
Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci (2002) 2.32
PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. J Nucl Med (2006) 2.20
Synthesis and evaluation in monkey of two sensitive 11C-labeled aryloxyanilide ligands for imaging brain peripheral benzodiazepine receptors in vivo. J Med Chem (2007) 2.11
Increased binding of peripheral benzodiazepine receptor in Alzheimer's disease measured by positron emission tomography with [11C]DAA1106. Biol Psychiatry (2008) 2.06
Species-specific calls evoke asymmetric activity in the monkey's temporal poles. Nature (2004) 2.04
Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med (2010) 2.00
Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. Proc Natl Acad Sci U S A (2013) 1.95
Brain and whole-body imaging in nonhuman primates of [11C]PBR28, a promising PET radioligand for peripheral benzodiazepine receptors. Neuroimage (2007) 1.91
Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med (2005) 1.89
Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 1.86
Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci (2007) 1.85
Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder. Biol Psychiatry (2012) 1.85
Radiation dosimetry and biodistribution in monkey and man of 11C-PBR28: a PET radioligand to image inflammation. J Nucl Med (2007) 1.81
Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. Am J Psychiatry (2003) 1.77
Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry (2002) 1.75
Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain (2004) 1.65
P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide. J Nucl Med (2010) 1.62
Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci (2004) 1.61
A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J Cereb Blood Flow Metab (2012) 1.59
In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. Brain (2013) 1.57
PET imaging with [11C]PBR28 can localize and quantify upregulated peripheral benzodiazepine receptors associated with cerebral ischemia in rat. Neurosci Lett (2006) 1.56
Fluoxetine administered to juvenile monkeys: effects on the serotonin transporter and behavior. Am J Psychiatry (2014) 1.54
Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET. Schizophr Res (2008) 1.53
Inhibitory effect of hippocampal 5-HT1A receptors on human explicit memory. Am J Psychiatry (2003) 1.53
P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys. J Nucl Med (2008) 1.53
Approaches to quantify radioligands that wash out slowly from target organs. Eur J Nucl Med Mol Imaging (2010) 1.52
Decreased neurokinin-1 (substance P) receptor binding in patients with panic disorder: positron emission tomographic study with [18F]SPA-RQ. Biol Psychiatry (2009) 1.47
The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci (2010) 1.46
The effect of scatter correction on 123I-IMP brain perfusion SPET with the triple energy window method in normal subjects using SPM analysis. Eur J Nucl Med Mol Imaging (2002) 1.45
No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by PET. Synapse (2003) 1.44
Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol Psychiatry (2006) 1.44
Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry (2010) 1.44
Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. J Med Chem (2008) 1.43
Image-derived input function for brain PET studies: many challenges and few opportunities. J Cereb Blood Flow Metab (2011) 1.42
Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand. Neuroimage (2009) 1.42
Application of calibrated image-derived input function to a clinical protocol. Nucl Med Commun (2014) 1.38
Age-related degeneration of corpus callosum measured with diffusion tensor imaging. Neuroimage (2006) 1.38
11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. J Nucl Med (2008) 1.37
Metabotropic glutamate subtype 5 receptors are quantified in the human brain with a novel radioligand for PET. J Nucl Med (2008) 1.37
Quantification of translocator protein (18 kDa) in the human brain with PET and a novel radioligand, (18)F-PBR06. J Nucl Med (2009) 1.36
Quantitative analyses of 18F-FEDAA1106 binding to peripheral benzodiazepine receptors in living human brain. J Nucl Med (2006) 1.36
Effects of early life stress on [11C]DASB positron emission tomography imaging of serotonin transporters in adolescent peer- and mother-reared rhesus monkeys. J Neurosci (2006) 1.36
Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry (2002) 1.35
Absolute quantification of regional cerebral glucose utilization in mice by 18F-FDG small animal PET scanning and 2-14C-DG autoradiography. J Nucl Med (2004) 1.35
Small effect of dopamine release and no effect of dopamine depletion on [18F]fallypride binding in healthy humans. Synapse (2008) 1.34
The PET radioligand [11C]MePPEP binds reversibly and with high specific signal to cannabinoid CB1 receptors in nonhuman primate brain. Neuropsychopharmacology (2007) 1.34
Kinetic evaluation in nonhuman primates of two new PET ligands for peripheral benzodiazepine receptors in brain. Synapse (2007) 1.34
Deficiency of schnurri-2, an MHC enhancer binding protein, induces mild chronic inflammation in the brain and confers molecular, neuronal, and behavioral phenotypes related to schizophrenia. Neuropsychopharmacology (2013) 1.33
Imaging neuroinflammation in Alzheimer's disease with radiolabeled arachidonic acid and PET. J Nucl Med (2008) 1.32
Image-derived input function for human brain using high resolution PET imaging with [C](R)-rolipram and [C]PBR28. PLoS One (2011) 1.31
Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using (18)F-labeled inverse agonist radioligands. J Nucl Med (2009) 1.31
Kinetic analysis in human brain of [11C](R)-rolipram, a positron emission tomographic radioligand to image phosphodiesterase 4: a retest study and use of an image-derived input function. Neuroimage (2010) 1.31
Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies. J Neurosci (2008) 1.29
Evaluation of anesthesia effects on [18F]FDG uptake in mouse brain and heart using small animal PET. Nucl Med Biol (2004) 1.27
Toward an evolutionary perspective on conceptual representation: species-specific calls activate visual and affective processing systems in the macaque. Proc Natl Acad Sci U S A (2004) 1.27
Brain incorporation of 11C-arachidonic acid, blood volume, and blood flow in healthy aging: a study with partial-volume correction. J Nucl Med (2004) 1.25